GOLDEN, Colo.– PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that their partner, Technovalia, has reported interim safety results from their needle-free SARS-CoV2 DNA vaccine phase 1 trial. Interim safety data of COVIGEN, their DNA COVID-19 vaccine candidate, is well tolerated and no safety concerns were observed.
The purpose of the phase 1 trial was to assess the safety and immunogenicity of two COVIGEN doses given one month apart to healthy volunteers aged 18 to 75 years of age who had not yet received a COVID-19 vaccination. Mr. Laurent Dapremont, Chief Executive Officer of Technovalia said, “We are pleased with these positive interim safety results from the ongoing COVALIA study which reinforce the existing pre-clinical data available. COVIGEN is the first plasmid-DNA vaccine to be tested in Australia and it is encouraging to observe no safety concern in the participants. We believe both mRNA and DNA vaccines will play an important role to combat the spread of COVID.” A study group will also assess COVIGEN as a booster dose on healthy subjects fully vaccinated.
Chris Cappello, President and CEO, PharmaJet commented, “We welcome this positive news and are proud to be part of the COVIGEN vaccine development with Technovalia, BioNet, and their Australian partners. These results are consistent with data from other DNA and RNA based vaccines administered using the PharmaJet Needle-free Injection Systems (NFIS). The PharmaJet NFIS is being used as the method of delivery on 20+ COVID vaccine development programs including the world’s first plasmid-based DNA vaccine recently receiving Emergency Use Authorization for COVID in India.”
